1439935-97-3

Upstream product

• 2050-45-5 N-acetyl-3,5-dimethylaniline 
• 779293-65-1 N-(4-(2-aminothiazol-4-yl)-3,5-dimethylphenyl)acetamide 
• 108-69-0 3,5-dimethylaminoaniline 
• 1439935-96-2 4-(2-aminothiazol-4-yl)-3,5-dimethylphenol 
• 37832-54-5 4-piperidinecarboxylic acid hydrochloride 
• 1439935-95-1 2-bromo-1-(4-hydroxy-2,6-dimethylphenyl)ethanone 
• 91060-92-3 1-(4-hydroxy-2,6-dimethylphenyl)ethanone 

Downstream Products

• 1439936-59-0 N-(4-{4-(6-(2-methoxyethylamino)pyridin-3-yloxy)-2,6-dimethylphenyl}thiazol-2-yl)isonicotinamide 
• 1439935-94-0 N-{4-(4-((6-hydroxypyridin-3-yl)oxy)-2,6-dimethylphenyl)thiazol-2-yl}isonicotinamide 
• 1439936-49-8 N-(4-{4-(2-(dimethylamino)ethoxy)-2,6-dimethylphenyl}thiazol-2-yl)isonicotinamide 
• 1439936-10-3 N-{4-(4-(6-methoxypyridin-3-yloxy)-2,6-dimethylphenyl)thiazol-2-yl}isonicotinamide 

Relevant academic research and scientific papers

SMALL MOLECULE MODIFIERS OF THE HEC1-NEK2 INTERACTION IN G2/M

Certain embodiments of the present invention provide selected compounds having a molecular structure according to Formula 1: In Formula 1, Z is —CO—, —SO—, or —SO2—; Ar is phenyl, heteroaryl, or heterocycloalkyl; Het is heteroaryl; R is R″, X,

IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR

Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases